JAMA
LightNews LightNews
banner
jama.com
JAMA
@jama.com
22K followers 110 following 2.3K posts
JAMA is an international peer-reviewed general medical journal and a member of the JAMA Network family of journals.

🌐 JAMA.com
Posts Replies Media Videos
jama.com
💬 Viewpoint: The One Big Beautiful Bill Act institutes new federal loan caps for medical students, increasing debt burden risks and barriers for aspiring physicians.

ja.ma/4qN1yxQ
JAMA editorial, published online November 10, 2025, discusses how federal loan caps burden medical students. Article by Katie Farkouh, Jacqueline Hogan, and Maxwell Barton addresses impacts of new loan limits.
November 10, 2025 at 5:30 PM
jama.com
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that predominantly affects women ages 40 to 60 years.

💡 This JAMA Insights discusses the clinical presentation, diagnosis, and treatment of PBC.

ja.ma/43T7yeF
Published online November 10, 2025, JAMA Insights, Primary Biliary Cholangitis, by Michele M. Tana, MD, MHS; Gideon M. Hirschfield, MA, MBBChir, PhD. Figure. Primary Biliary Cholangitis (PBC)—From Diagnosis to Personalized Care.
November 10, 2025 at 5:15 PM
jama.com
"During the last two decades, the prevalence almost doubled."

Author Norbert Stefan, MD, from the University Hospital of Tübingen discusses metabolic dysfunction-associated steatotic liver disease (MASLD) with JAMA Deputy Editor Kristin Walter, MD, MS.

ja.ma/442IqlH
JAMA Clinical Reviews podcast cover with 'Diagnosis and Treatment of MASLD' title. Features a beige background with 'Clinical Reviews' text and a red 'JN' logo. The word 'JAMA' is vertically oriented on the left.
November 10, 2025 at 5:12 PM
jama.com
The most common chronic liver disease worldwide, metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately 30% to 40% of the general adult population.

This Review summarizes the diagnosis, treatment, and prognosis of MASLD. ja.ma/3XiORgN
Figure outlines MASLD progression from healthy liver to cirrhosis/hepatic decompensation. Factors promoting MASLD include diet, insulin resistance; protective factors: physical exercise, socioeconomic status. Progression rates are shown. Text: JAMA, Published online November 10, 2025.
November 10, 2025 at 4:30 PM
jama.com
Viewpoint by FDA Commissioner of Food and Drugs Martin Makary, MD, MPH, et al: Labeling changes for estrogen and progestogen products now emphasize individualized care, updated risk communication, and differences across systemic vs topical therapies.

ja.ma/3JQqSm4
A JAMA article titled 'Updated Labeling for Menopausal Hormone Therapy' by Martin A. Makary et al., published online November 10, 2025. Article discusses estrogen replacement and FDA labeling changes for menopausal hormone therapy.
November 10, 2025 at 4:15 PM
jama.com
💬 Viewpoint: Safeguarding pathways for non-US international medical graduates (IMGs) is essential to addressing physician shortages and ensuring health care access in underserved regions.

ja.ma/43nn8it
A JAMA article cover dated September 25, 2025, titled "International Medical Graduates, Visa Disruptions, and the Future of the US Physician Workforce" by Natalia Solenkova, discussing J-1 visa processing vulnerabilities.
November 10, 2025 at 2:00 PM
jama.com
💬 Viewpoint: Increasing unionization among medical trainees highlights the complex interplay of financial pressures, working conditions, and educational goals in health care systems.

ja.ma/3JDXQpK
A page from JAMA, published September 25, 2025, titled 'Reflections on Medical Trainee Unions and Health Care Systems' by Peter J. Frederick et al. It discusses unionization trends, benefits, and the context within the healthcare ecosystem.
November 10, 2025 at 1:00 PM
jama.com
💬 Viewpoint: Medical education should shift from pattern recognition to critical thinking and pathophysiological reasoning to reduce diagnostic errors and adapt to #AI advancements. #MedEd

ja.ma/4oZM2wP
Flowchart comparing illness script-based vs. pathophysiological approaches to patient diagnosis. The script-based approach starts with symptoms like nocturnal respiratory distress and ends with diuretics, while the pathophysiological approach starts with hypoxemia, and ends with CPAP.
November 10, 2025 at 12:00 PM
jama.com
In this #AHA25 edition of the JAMA Editor’s Summary podcast, Gregory Curfman, MD, Philip Greenland, MD, and Robert Bonow, MD, MS, review key JAMA Network articles, including:

➡️ Coffee and #AFib,
➡️ DASH-patterned groceries,
➡️ Oral PCSK9 inhibitor enlicitide, and more.

🎧 Listen now: ja.ma/47MpAAj
Close-up of JAMA journals stacked. The covers feature 'JAMA' in bold letters. Below, text reads: 'From AHA: Coffee Consumption and Atrial Fibrillation, DASH-... JAMA Editors' Summary'. A purple 'Play' button is visible.
November 9, 2025 at 11:35 PM
jama.com
📖 Read all the JAMA, @jamacardiology.com, @jamainternalmed.com, and @jamanetworkopen.com papers presented today at #AHA25.

➡️ ja.ma/43PkF0s
November 9, 2025 at 11:20 PM
jama.com
💬 Editorial: While early detection and treatment may help some high-risk youth, the study by Bellows et al suggests broader population approaches to lower LDL-C distribution may offer greater cost-effectiveness.

#AHA25 @ahascience.bsky.social

ja.ma/4hMcFD6
A page from JAMA, published online November 9, 2025, titled "Childhood Cholesterol Screening Is Not Cost-Effective" by Matthew W. Gillman, MD, SM. The editorial discusses the controversy and complexities of childhood cholesterol screening.
November 9, 2025 at 11:20 PM
jama.com
Sequential childhood or early adulthood screening for familial hypercholesterolemia may lower lifetime CVD risk but is unlikely to be cost-effective unless follow-up for elevated cholesterol is widely implemented.

#AHA25 @ahascience.bsky.social

ja.ma/4oAh7rp
JAMA. Article: Familial Hypercholesterolemia Screening in Childhood and Early Adulthood: A Cost-Effectiveness Study. Figure 2 shows cost-effectiveness outcomes with scatterplot and acceptability curve, stratified by LDL-C Threshold.
November 9, 2025 at 11:20 PM
jama.com
From @jamainternalmed.com: A 6-month habit-based group lifestyle intervention added to routine education and activity monitoring improved the proportion of patients with sustained metabolic syndrome remission.

#AHA25 @ahascience.bsky.social

ja.ma/4oI5cHO
JAMA Internal Medicine study on lifestyle intervention for metabolic syndrome remission. 618 participants randomized into group-based lifestyle intervention or enhanced usual care. Results show treatment group achieved higher remission at 24 months.
November 9, 2025 at 11:20 PM
jama.com
💬 Editorial: The GoFresh trial showed home-delivered DASH groceries modestly lowered BP and LDL cholesterol in Black adults, but high costs and diet design limit broader impact.

#AHA25 @ahascience.bsky.social

ja.ma/43kGqFf
An editorial from JAMA, published online November 9, 2025, titled "Medically Tailored Groceries for Blood Pressure Control: Promise, Progress, and Need for Optimal Design" by Dariush Mozaffarian, MD, DrPH.
November 9, 2025 at 11:20 PM
jama.com
Home-delivered, low-sodium Dietary Approaches to Stop Hypertension (DASH) groceries and dietitian support temporarily improved blood pressure and LDL cholesterol in Black adults with high BP versus monetary support.

#AHA25 @ahascience.bsky.social

ja.ma/43lTKt2
Infographic from JAMA about a study on blood pressure. It shows that home-delivered, DASH diet-targeted groceries with dietitian counseling lowered blood pressure among Black adults. The study included 102 women and 78 men with a mean age of 46 years.
November 9, 2025 at 11:20 PM
jama.com
💬 Editorial: The CORALreef HeFH trial demonstrated that oral enlicitide achieves robust, sustained reductions in LDL-C and other atherogenic lipids in patients with heterozygous familial hypercholesterolemia already receiving statin therapy.

#AHA25 @ahascience.bsky.social

ja.ma/4hOzaY5
A JAMA article titled "Beyond Statins—Expanding the Arsenal of Lipid-Lowering Therapies" by Michelle L. O'Donoghue, MD, MPH; Nicholas A. Marston, MD, MPH, published online November 9, 2025, discusses advancements in lipid-lowering treatments.
November 9, 2025 at 11:20 PM
jama.com
Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).

#AHA25 @ahascience.bsky.social

ja.ma/4nQHAzM
JAMA study: Oral PCSK9 inhibitor enlicitide effectively reduces low-density lipoprotein cholesterol in adults with heterozygous familial hypercholesterolemia. Enlicitide group: -58.2% change. Placebo: 2.6%.
November 9, 2025 at 11:20 PM
jama.com
From @jamanetworkopen.com: For neonates with congenital heart defects (CHDs) in Illinois, delayed #prenatal care initiation was associated with a higher probability of delivery at a pediatric #cardiac center, especially for severe CHD.

#AHA25 @ahascience.bsky.social

ja.ma/4hWAVTq
JAMA Network Open article published November 9, 2025, titled "Prenatal Care and Perinatal Regionalization for Congenital Heart Defects" explores links between prenatal care and delivery location for babies with heart defects.
November 9, 2025 at 11:20 PM
jama.com
From @jamacardiology.com: Flynn et al find non-DNMT3A clonal hematopoiesis of indeterminate potential (CHIP) mutations most strongly associated with heart failure risk in UK Biobank data, supporting gene-specific risk assessment.

#AHA25 @ahascience.bsky.social

ja.ma/3JFEXmo
JAMA Cardiology publication cover dated November 9, 2025. The title reads, "Clonal Hematopoiesis—An Opportunity to Confront the Heart Failure Epidemic" by Domingo A. Pascual-Figal, MD, PhD; José J. Fuster, PhD.
November 9, 2025 at 11:20 PM
jama.com
From @jamacardiology.com: Non-DNMT3A clonal hematopoiesis of indeterminate potential (CHIP) subtypes—including TET2, ASXL1, JAK2, and spliceosome genes—demonstrated higher association with incident heart failure compared to DNMT3A.

#AHA25 @ahascience.bsky.social

ja.ma/3XiNpLg
A bar graph titled 'Mediation Analyses for Non-DNMT3A Clonal Hematopoiesis of Indeterminant Potential (CHIP) and Incident Heart Failure' shows 'Percentage mediated' on the Y axis and 'Mediator' on the X axis with bars for artery disease, atrial fibrillation, diabetes, etc.
November 9, 2025 at 11:20 PM
jama.com
From @jamanetworkopen.com: Compared to standard regimens, trastuzumab emtansine exhibited a more favorable cardiotoxicity profile, while other novel and standard therapies demonstrated comparable risks of LVEF decline.

#AHA25 @ahascience.bsky.social

ja.ma/4hUqr6T
JAMA Network Open publication from November 9, 2025, titled "Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis" by Lakshya Seth et al.
November 9, 2025 at 11:20 PM
jama.com
📊 Research Summary: Adults with #AFib who drank at least one cup of caffeinated coffee daily after successful cardioversion had a lower risk of recurrence than those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/4hRnJz2
JAMA Research Summary: Caffeinated coffee consumption vs abstinence to reduce atrial fibrillation. Consuming coffee may reduce atrial fibrillation episodes. 47% recurrence with coffee vs. 64% with abstinence over 6 months. 200 participants analyzed.
November 9, 2025 at 11:20 PM
jama.com
Patients with #AFib who continued their usual caffeinated coffee intake after cardioversion experienced less recurrence of AF or atrial flutter compared to those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/47xVRMT
Infographic summarizing a JAMA study on coffee and atrial fibrillation (AF). It concludes that consuming caffeinated coffee (1 cup/day) is linked to less AF recurrence compared to abstaining. The study involved 200 patients, mean age 69, across 5 hospitals.
November 9, 2025 at 11:20 PM
jama.com
💾 Save this thread! Check out these key findings from today's JAMA, @jamacardiology.com, @jamainternalmed.com, and
@jamanetworkopen.com presentations at #AHA25. 🧵

Adding coronary CT angiography to traditional risk scores modestly improved prediction of first coronary events. ja.ma/4oyzvko
Four graphs from a JAMA article titled 'Coronary Computed Tomography Angiography in Prediction of First Coronary Events'. The graphs show 'Cumulative Incidence of Coronary Events', charting coronary event rates by CACS, SIS, stenosis, and calcification.
November 9, 2025 at 11:20 PM
jama.com
Robert Bonow, MD, MS, is celebrated at #AHA25. Dr Bonow, founding editor of JAMA Cardiology, marked 10 years as its Editor in Chief.
Robert Bonow, MD, MS, is celebrated at #AHA25. Robert Bonow, MD, MS, is celebrated at #AHA25.
November 9, 2025 at 11:02 PM